Company Profile, Products & Technologies, Target Market

Immunovative Therapies, Ltd (ITL) is an early stage Israeli biopharmaceutical company specializing in the development of immunotherapy products for treatment of cancer and infectious disease where the active ingredients are living allogeneic immune cells. The Company has completed pre-clinical evaluation of an allogeneic cell product formulated with monoclonal antibody-conjugated biodegradable nanoparticles called AlloStim. AlloStim is designed to elicit the same curative anti-tumor effect that occurs in allogeneic bone marrow transplantation without the toxic and often lethal GVHD side-effect. AlloStim will be tested in Phase I/II clinical trials of Chronic Lymphocytic Leukemia (CLL) and in combination with cryoablation surgery in advanced prostate, colon and kidney cancers.

Brief description of proposed R&D project:

Pre-clinical results have demonstrated the strong adjuvant effect of AlloStim as a stimulator of innate immunity and its ability to mature dendritic cells to elicit Th1 immunity and break tolerance. These properties are thought to be beneficial in the design of a therapeutic vaccine for hepatitis C, which avoids the immune response by producing IL-10. We propose to work with a partner to develop a source of attenuated hepatitis C conjugated with chaparone proteins which will be formulated with AlloStim and administered to alloantigen-primed patients with hepatitis C infection as therapeutic vaccine.

Desired Profile of R&D Partner and its role in the proposed project:

We are seeking a partner with the facilities and expertise to develop a cell culture system to produce and purify attenuated hepatitis C virus and chaparone proteins. ITL will conduct phase I/II clinical trials of the proposed combination vaccine/AlloStim product at its clinical research center located in California USA.